Feng-Cai Zhu, et al. "Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial." The Lancet (2020). https://doi.org/10.1016/S0140-6736(20)31208-3
Gray, Glenda E., et al. "Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study." The Lancet infectious diseases 14.5 (2014): 388-396.
Freedman, Mark S. The Role of Neutralizing Antibodies in MS Treatments. Medscape. August 30, 2003 [2009-08-04].